Merck Stock Slips on Earnings Release, Tests Key Support Level
Merck's stock price has fallen by 1.85% to $127.80 as it tests its key support level at $127.61. The decline comes after the company posted its second quarter 2026 earnings results on social media, without providing any detailed financial figures or performance drivers.
The announcement, made via Merck's official account, invited followers to view comments from Chairman and CEO Rob Davis. However, no specific market factors such as revenue or costs were mentioned or implied in the announcement.
Despite the decline, shares are still above their moving averages (MA-20, MA-50, and MA-200) and technical indicators show an oversold reading, limiting further downside. The Ichimoku Kijun support level at $127.61 is currently being tested, with a 70% probability of an upside move and a 30% chance of a decline.